Tayo Sanders II

Company: Singular Immune

Job title: Chief Business Officer

Seminars:

Engineering Immune Precision In Situ: A Protein-Based Approach to CAR Conversion 1:30 pm

Introducing the iCAR paradigm: using engineered proteins to transform immune cells into CAR effectors inside the patient—without gene editing or viral vectors  Demonstrating the systemic delivery of recombinant iCAR-NK PD-L1 protein to generate in vivo CAR-NK cells targeting PD-L1+ tumors in humanized models  Outlining our next step: dual iCAR-NK/T protein targeting TROP2 to broaden efficacy…Read more

day: Day Two

Panel Discussion: ‘Evaluating LVV & LNP Delivery Method Clinical Potential in In Vivo Cell & Gene Therapies 2:00 pm

Discussing the long-term efficacy and durability of LVV and LNP-based therapies to understand the impact of delivery on disease regression and treatment Exploring how LVV, LNP and RNP technologies can evolve to produce enhanced therapeutic outcomes Evaluating the potential of the delivery vehicles to deliver complex payloadsRead more

day: Day Two